Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19 CAR-T cells with TNFAIP3 variants
- Development stage
- Preclinical
- Lead developer
- Carina Biotech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-CD19 CAR-T cells with TNFAIP3 variants are an experimental cell therapy designed to treat B-cell malignancies. Developed by researchers at the Garvan Institute and Carina Biotech, these third-generation CAR-T cells are genetically engineered to express specific reduction-of-function variants of the *TNFAIP3* gene (also known as A20). TNFAIP3 normally acts as a negative regulator of NF-κB signaling; by introducing variants that reduce its activity, the CAR-T cells exhibit a lower activation threshold, increased secretion of effector cytokines, and enhanced cytotoxic activity. This approach aims to overcome T cell exhaustion and improve therapeutic persistence in the face of chronic antigen stimulation.
- Other names
- TNFAIP3-modified anti-CD19 CAR-T cellsTNFAIP-3-modified anti-CD19 CAR-T cellsTNFAIP 3-modified anti-CD19 CAR-T cellsA20-modified anti-CD19 CAR-T cellsA-20-modified anti-CD19 CAR-T cellsA 20-modified anti-CD19 CAR-T cells
02
Targets
CD19 (B lymphocyte antigen CD19)TNFAIP3 (Tumor necrosis factor alpha-induced protein 3)
Beyond the preview
Go deeper on anti-CD19 CAR-T cells with TNFAIP3 variants.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19 CAR-T cells with TNFAIP3 variants.